FDA Approves Frontline Alectinib for ALK-Positive NSCLC

The FDA has approved alectinib (Alecensa) for the frontline treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC), according to Genentech (Roche), the manufacturer of the second-generation ALK inhibitor.